Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Together, we are committed to making a difference – to patients, the healthcare system and the society in which we are embedded.
Basilea at a glance
Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and several preclinical anti-infective assets. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.
Vision and mission
People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.
Organization
Board of directors







Board committees
Audit committee | Compensation committee | Corporate governance & nomination committee |
Leonard Kruimer (Chairman) | Dr. Martin Nicklasson (Chairman) | Dr. Thomas Werner (Chairman) |
Dr. Martin Nicklasson | Dr. Nicole Onetto | Domenico Scala |
Steven D. Skolsky | Dr. Thomas Werner | Steven D. Skolsky |
For further information on the responsibilities of the board committees, please refer to the latest annual report.
Management committee
Extended management committee